Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine

A live attenuated vaccine reduces the burden of herpes zoster (shingles) in older adults, according to the recently published results of a randomised, double-blind trial

Download Full-text

P195: Co-administration of herpes zoster live-attenuated vaccine with polysaccharide pneumococcal-23 vaccine

European Geriatric Medicine ◽

10.1016/s1878-7649(14)70370-5 ◽

2014 ◽

Vol 5 ◽

pp. S145

Author(s):

I. Bertrand ◽

S. Thomas ◽

G. Kassianos

Keyword(s):

Herpes Zoster ◽

Live Attenuated Vaccine ◽

Attenuated Vaccine

Download Full-text

Effective Vaccination Program for Squabs from Vaccinated and NonVaccinated Pigeons with Tissue Culture Adapted Pigeon Pox Live Attenuated Vaccine Regarding Maternal Immunity

Journal of Applied Veterinary Sciences ◽

10.21608/javs.2021.104273.1113 ◽

2022 ◽

Vol 7 (1) ◽

pp. 53-57

Author(s):

Kafafy M.H. ◽

Ayatollah I. Ibrahim

Keyword(s):

Tissue Culture ◽

Vaccination Program ◽

Live Attenuated Vaccine ◽

Maternal Immunity ◽

Attenuated Vaccine

Download Full-text

Monitoring Interest in Herpes Zoster Vaccination: Analysis of Google Search Data (Preprint)

10.2196/preprints.10180 ◽

2018 ◽

Author(s):

Elyse J Berlinberg ◽

Michael S Deiner ◽

Travis C Porco ◽

Nisha R Acharya

Keyword(s):

Public Health ◽

Herpes Zoster ◽

Vaccine Coverage ◽

Application Programming Interface ◽

The United States ◽

Live Attenuated Vaccine ◽

Attenuated Vaccine ◽

Search Volume ◽

Search Data ◽

Google Search

BACKGROUND A new recombinant subunit vaccine for herpes zoster (HZ or shingles) was approved by the United States Food and Drug Administration on October 20, 2017 and is expected to replace the previous live attenuated vaccine. There have been low coverage rates with the live attenuated vaccine (Zostavax), ranging from 12-32% of eligible patients receiving the HZ vaccine. OBJECTIVE This study aimed to provide insight into trends and potential reasons for interest in HZ vaccination. METHODS Internet search data were queried from the Google Health application programming interface from 2004-2017. Seasonality of normalized search volume was analyzed using wavelets and Fisher’s g test. RESULTS The search terms “shingles vaccine,” “zoster vaccine,” and “zostavax” all exhibited significant periodicity in the fall months (P<.001), with sharp increases after recommendations for vaccination by public health-related organizations. Although the terms “shingles blisters,” “shingles itch,” “shingles rash,” “skin rash,” and “shingles medicine” exhibited statistically significant periodicities with a seasonal peak in the summer (P<.001), the terms “shingles contagious,” “shingles pain,” “shingles treatment,” and “shingles symptoms” did not reveal an annual trend. CONCLUSIONS There may be increased interest in HZ vaccination during the fall and after public health organization recommendations are broadcast. This finding points to the possibility that increased awareness of the vaccine through public health announcements could be evaluated as a potential intervention for increasing vaccine coverage.

Download Full-text

Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis

BMJ ◽

10.1136/bmj.k4029 ◽

2018 ◽

pp. k4029 ◽

Cited By ~ 30

Author(s):

Andrea C Tricco ◽

Wasifa Zarin ◽

Roberta Cardoso ◽

Areti-Angeliki Veroniki ◽

Paul A Khan ◽

...

Keyword(s):

Herpes Zoster ◽

Adverse Events ◽

Randomised Controlled Trials ◽

Subunit Vaccine ◽

Meta Analysis ◽

Controlled Trials ◽

Live Attenuated Vaccine ◽

Recombinant Subunit Vaccine ◽

Attenuated Vaccine ◽

Randomised Controlled

AbstractObjectiveTo compare the efficacy, effectiveness, and safety of the herpes zoster live attenuated vaccine with the herpes zoster adjuvant recombinant subunit vaccine or placebo for adults aged 50 and older.DesignSystematic review with bayesian meta-analysis and network meta-analysis.Data sourcesMedline, Embase, and Cochrane Library (inception to January 2017), grey literature, and reference lists of included studies.Eligibility criteria for study selectionExperimental, quasi-experimental, and observational studies that compared the live attenuated vaccine with the adjuvant recombinant subunit vaccine, placebo, or no vaccine in adults aged 50 and older. Relevant outcomes were incidence of herpes zoster (primary outcome), herpes zoster ophthalmicus, post-herpetic neuralgia, quality of life, adverse events, and death.Results27 studies (22 randomised controlled trials) including 2 044 504 patients, along with 18 companion reports, were included after screening 2037 titles and abstracts, followed by 175 full text articles. Network meta-analysis of five randomised controlled trials found no statistically significant differences between the live attenuated vaccine and placebo for incidence of laboratory confirmed herpes zoster. The adjuvant recombinant subunit vaccine, however, was statistically superior to both the live attenuated vaccine (vaccine efficacy 85%, 95% credible interval 31% to 98%) and placebo (94%, 79% to 98%). Network meta-analysis of 11 randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more adverse events at injection sites than the live attenuated vaccine (relative risk 1.79, 95% credible interval 1.05 to 2.34; risk difference 30%, 95% credible interval 2% to 51%) and placebo (5.63, 3.57 to 7.29 and 53%, 30% to 73%, respectively). Network meta-analysis of nine randomised controlled trials showed the adjuvant recombinant subunit vaccine to be associated with statistically more systemic adverse events than placebo (2.28, 1.45 to 3.65 and 20%, 6% to 40%, respectively).ConclusionsUsing the adjuvant recombinant subunit vaccine might prevent more cases of herpes zoster than using the live attenuated vaccine, but the adjuvant recombinant subunit vaccine also carries a greater risk of adverse events at injection sites.Protocol registrationProspero CRD42017056389.

Download Full-text

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial

Vaccine ◽

10.1016/j.vaccine.2014.12.024 ◽

2015 ◽

Vol 33 (6) ◽

pp. 789-795 ◽

Cited By ~ 26

Author(s):

Javier Diez-Domingo ◽

Thomas Weinke ◽

Juan Garcia de Lomas ◽

Claudius U. Meyer ◽

Isabelle Bertrand ◽

...

Keyword(s):

Clinical Trial ◽

Herpes Zoster ◽

Subcutaneous Administration ◽

Live Attenuated Vaccine ◽

Attenuated Vaccine

Download Full-text

Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model

PLoS ONE ◽

10.1371/journal.pone.0251644 ◽

2021 ◽

Vol 16 (5) ◽

pp. e0251644

Author(s):

Ellen Wolff ◽

Katarina Widgren ◽

Gianpaolo Scalia Tomba ◽

Adam Roth ◽

Tiia Lep ◽

...

Keyword(s):

Herpes Zoster ◽

Cost Effectiveness ◽

Vaccination Programme ◽

Cost Effective ◽

Transmission Model ◽

Varicella Vaccination ◽

Economic Evaluations ◽

Live Attenuated Vaccine ◽

Attenuated Vaccine ◽

National Vaccination Programme

Objectives Comprehensive cost-effectiveness analyses of introducing varicella and/or herpes zoster vaccination in the Swedish national vaccination programme. Design Cost-effectiveness analyses based on epidemiological results from a specifically developed transmission model. Setting National vaccination programme in Sweden, over an 85- or 20-year time horizon depending on the vaccination strategy. Participants Hypothetical cohorts of people aged 12 months and 65-years at baseline. Interventions Four alternative vaccination strategies; 1, not to vaccinate; 2, varicella vaccination with one dose of the live attenuated vaccine at age 12 months and a second dose at age 18 months; 3, herpes zoster vaccination with one dose of the live attenuated vaccine at 65 years of age; and 4, both vaccine against varicella and herpes zoster with the before-mentioned strategies. Main outcome measures Accumulated cost and quality-adjusted life years (QALY) for each strategy, and incremental cost-effectiveness ratios (ICER). Results It would be cost-effective to vaccinate against varicella (dominant), but not to vaccinate against herpes zoster (ICER of EUR 200,000), assuming a cost-effectiveness threshold of EUR 50,000 per QALY. The incremental analysis between varicella vaccination only and the combined programme results in a cost per gained QALY of almost EUR 1.6 million. Conclusions The results from this study are central components for policy-relevant decision-making, and suggest that it was cost-effective to introduce varicella vaccination in Sweden, whereas herpes zoster vaccination with the live attenuated vaccine for the elderly was not cost-effective–the health effects of the latter vaccination cannot be considered reasonable in relation to its costs. Future observational and surveillance studies are needed to make reasonable predictions on how boosting affects the herpes zoster incidence in the population, and thus the cost-effectiveness of a vaccination programme against varicella. Also, the link between herpes zoster and sequelae need to be studied in more detail to include it suitably in health economic evaluations.

Download Full-text